455.45

-0.62%↓

SANES

9.402

-0.61%↓

SAF

276.5

-1.67%↓

BBVA

17.955

-1.45%↓

BNP

81.05

-0.92%↓

455.45

-0.62%↓

SANES

9.402

-0.61%↓

SAF

276.5

-1.67%↓

BBVA

17.955

-1.45%↓

BNP

81.05

-0.92%↓

455.45

-0.62%↓

SANES

9.402

-0.61%↓

SAF

276.5

-1.67%↓

BBVA

17.955

-1.45%↓

BNP

81.05

-0.92%↓

455.45

-0.62%↓

SANES

9.402

-0.61%↓

SAF

276.5

-1.67%↓

BBVA

17.955

-1.45%↓

BNP

81.05

-0.92%↓

455.45

-0.62%↓

SANES

9.402

-0.61%↓

SAF

276.5

-1.67%↓

BBVA

17.955

-1.45%↓

BNP

81.05

-0.92%↓

Начало・Списък с акции・Ipsen SA.

Ipsen SA.

Затворен

СекторФинансови

157.2 3.69

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

154.8

Максимум

158.9

Ключови измерители
By Trading Economics
Приходи	-225M 110M
Продажби	36M 1.9B
P/E Средно за сектора	27.842 54.484
Дивидентна доходност	0.94
Марж на печалбата	5.899
Служители	5,535
EBITDA	-171M 466M

Препоръки
By TipRanks
Препоръки	Неутрален
12-месечна прогноза	-7.51% downside

Дивиденти
By Dow Jones
Дивидентна доходност Средно за сектора	0.94% 4.92%

Пазарни показатели
By TradingEconomics
Пазарна капитализация	866M 12B
Предишно отваряне	153.51
Предишно затваряне	157.2

Настроения в новините

By Acuity

48%

52%

161 / 441 Класиране в Finance

Техническа оценка

By Trading Central

Увереност

Strong Bullish Evidence

99.85 / 104 Подкрепа & съпротива

Ipsen SA. Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

27.03.2026 г., 17:33 ч. UTC

Значими събития в новините

ECB Should Not Rush Its Response to Iran Conflict, Says Schnabel -- Update

27.03.2026 г., 17:00 ч. UTC

Значими събития в новините

ECB Shouldn't Rush Its Response to Iran Conflict, Schnabel Says

27.03.2026 г., 16:03 ч. UTC

Значими събития в новините

Fertilizer Maker Yara Warns Farmers Are Being Squeezed by Price Surge Amid War -- Commodities Roundup

27.03.2026 г., 14:50 ч. UTC

Значими двигатели на пазара

Cybersecurity Stocks Fall on Leak About New Claude Model's Cyber Capabilities

27.03.2026 г., 14:37 ч. UTC

Придобивния, сливания и поглъщания

Nestle's Water Business Stake Sale Could Value Unit at Around $5.76 billion, FT Says, Citing Sources

27.03.2026 г., 14:29 ч. UTC

Значими събития в новините

EU Finance Ministers Tally Economic Hit of Iran War -- Update

27.03.2026 г., 14:16 ч. UTC

Значими събития в новините

The Week in Oil: Mixed Signals Over U.S.-Iran Talks Keep Traders Wary

27.03.2026 г., 20:50 ч. UTC

Пазарно говорене

Health Care Roundup: Market Talk

27.03.2026 г., 19:16 ч. UTC

Пазарно говорене

Значими събития в новините

Oil Futures Rise On Uncertainty Ahead of Weekend -- Market Talk

27.03.2026 г., 19:07 ч. UTC

Пазарно говорене

U.S. Natural Gas Gains As April Contract Expires -- Market Talk

27.03.2026 г., 19:04 ч. UTC

Пазарно говорене

Gold Rises But Can't Finish the Week Positive -- Market Talk

27.03.2026 г., 19:03 ч. UTC

Пазарно говорене

Значими събития в новините

Global Forex and Fixed Income Roundup: Market Talk

27.03.2026 г., 19:02 ч. UTC

Пазарно говорене

Значими събития в новините

Among Central Banks, Canada Has Room to Handle Oil Inflation -- Market Talk

27.03.2026 г., 18:12 ч. UTC

Пазарно говорене

Foreign Fuels and Feedstocks to Get RINs Until 2028 -- Market Talk

27.03.2026 г., 17:36 ч. UTC

Значими събития в новините

The Iran War and Oil Prices Bring Risk of Deeper Market Lows. There Are Echoes of 2008. -- Barrons.com

27.03.2026 г., 17:34 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Delivery Hero Shares Bounce as Stake-Sale Report Whets Investor Appetites -- Market Talk

27.03.2026 г., 17:29 ч. UTC

Пазарно говорене

U.S. Oil Rig Count Falls By 5 to 409 -- Market Talk

27.03.2026 г., 16:38 ч. UTC

Пазарно говорене

Carnival's Outlook Assumes Oil Prices Will Come Down -- Market Talk

27.03.2026 г., 16:32 ч. UTC

Пазарно говорене

Значими събития в новините

Chinese Exposure to Higher Energy Costs Seen as Limited -- Market Talk

27.03.2026 г., 16:20 ч. UTC

Пазарно говорене

Health Care Roundup: Market Talk

27.03.2026 г., 15:43 ч. UTC

Пазарно говорене

Значими събития в новините

Hormuz Closure Sends Tanker Rates to Record Highs -- Market Talk

27.03.2026 г., 15:25 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

27.03.2026 г., 15:25 ч. UTC

Пазарно говорене

Swiss Franc Dented by Rising European Yields, SNB Intervention Threats -- Market Talk

27.03.2026 г., 15:00 ч. UTC

Значими събития в новините

Fed's Barkin: Inflation Progress 'May Be at Risk of Stalling'

27.03.2026 г., 15:00 ч. UTC

Значими събития в новините

Fed's Barkin: Holding Rates Steady in March 'Felt Prudent'

27.03.2026 г., 15:00 ч. UTC

Значими събития в новините

Fed's Barkin Says Iran War Raising Economic Uncertainty

27.03.2026 г., 14:36 ч. UTC

Пазарно говорене

Значими събития в новините

Rising Yields, Oil Prices Seen as Overreaction -- Market Talk

27.03.2026 г., 14:26 ч. UTC

Пазарно говорене

Значими събития в новините

Treasury Yields Mixed as Iran Peace Deal Remains Elusive -- Market Talk

27.03.2026 г., 14:14 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

27.03.2026 г., 14:14 ч. UTC

Пазарно говорене

Global Energy Roundup: Market Talk

Сравнение с други в отрасъла

Ценова промяна

Ipsen SA. Прогноза

Ценова цел

By TipRanks

-7.51% надолу

12-месечна прогноза

Среден 141.33 EUR -7.51%

Висок 155 EUR

Нисък 132 EUR

Според 3 анализатори от Wall Street, предложили 12-месечна ценова цел за Ipsen SA. през последните три месеца.

Консенсусна оценка

By TipRanks

Неутрален

3 ratings

Купи

Задържане

Продай

Според 3 анализатори, дали борсови рейтинги на Ipsen SA. през последните 3 месеца.

Техническа оценка

By Trading Central

99.85 / 104Подкрепа & съпротива

Bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

Настроение

By Acuity

161 / 441 Класиране в Финансови

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Ipsen SA.

Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial. The company also offers Somatuline, Decapeptyl, Cabometyx, Onivyde, Tazverik, and other oncology products; Dysport and other neurosciences products; and Bylvay, NutropinAq, Increlex, and Sohonos for rare diseases. The company was founded in 1929 and is based in Boulogne-Billancourt, France.